ID   GALT3_HUMAN             Reviewed;         633 AA.
AC   Q14435; Q53TG9; Q7Z476;
DT   16-AUG-2004, integrated into UniProtKB/Swiss-Prot.
DT   14-OCT-2008, sequence version 2.
DT   03-AUG-2022, entry version 187.
DE   RecName: Full=Polypeptide N-acetylgalactosaminyltransferase 3;
DE            EC=2.4.1.41;
DE   AltName: Full=Polypeptide GalNAc transferase 3;
DE            Short=GalNAc-T3;
DE            Short=pp-GaNTase 3;
DE   AltName: Full=Protein-UDP acetylgalactosaminyltransferase 3;
DE   AltName: Full=UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3;
GN   Name=GALNT3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Salivary gland;
RX   PubMed=8663203; DOI=10.1074/jbc.271.29.17006;
RA   Bennett E.P., Hassan H., Clausen H.;
RT   "cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-
RT   galactosamine polypeptide N-acetylgalactosaminyltransferase, GalNAc-T3.";
RL   J. Biol. Chem. 271:17006-17012(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=9295285; DOI=10.1074/jbc.272.38.23503;
RA   Wandall H.H., Hassan H., Mirgorodskaya E., Kristensen A.K., Roepstorff P.,
RA   Bennett E.P., Nielsen P.A., Hollingsworth M.A., Burchell J.,
RA   Taylor-Papadimitriou J., Clausen H.;
RT   "Substrate specificities of three members of the human UDP-N-acetyl-alpha-
RT   D-galactosamine:polypeptide N-acetylgalactosaminyltransferase family,
RT   GalNAc-T1, -T2, and -T3.";
RL   J. Biol. Chem. 272:23503-23514(1997).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9394011; DOI=10.1242/jcs.111.1.45;
RA   Roettger S., White J., Wandall H.H., Olivo J.-C., Stark A., Bennett E.P.,
RA   Whitehouse C., Berger E.G., Clausen H., Nilsson T.;
RT   "Localization of three human polypeptide GalNAc-transferases in HeLa cells
RT   suggests initiation of O-linked glycosylation throughout the Golgi
RT   apparatus.";
RL   J. Cell Sci. 111:45-60(1998).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=12708471; DOI=10.1111/j.1349-7006.2003.tb01348.x;
RA   Onitsuka K., Shibao K., Nakayama Y., Minagawa N., Hirata K., Izumi H.,
RA   Matsuo K., Nagata N., Kitazato K., Kohno K., Itoh H.;
RT   "Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine:polypeptide
RT   N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with
RT   gastric carcinoma.";
RL   Cancer Sci. 94:32-36(2003).
RN   [8]
RP   INVOLVEMENT IN HFTC1, AND VARIANT HFTC 162-ARG--ASP-633 DEL.
RX   PubMed=15133511; DOI=10.1038/ng1358;
RA   Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M.,
RA   Khamaysi Z., Behar D., Petronius D., Friedman V., Zelikovic I., Raimer S.,
RA   Metzker A., Richard G., Sprecher E.;
RT   "Mutations in GALNT3, encoding a protein involved in O-linked
RT   glycosylation, cause familial tumoral calcinosis.";
RL   Nat. Genet. 36:579-581(2004).
RN   [9]
RP   INVOLVEMENT IN HFTC1.
RX   PubMed=15599692; DOI=10.1007/s00109-004-0610-8;
RA   Frishberg Y., Topaz O., Bergman R., Behar D., Fisher D., Gordon D.,
RA   Richard G., Sprecher E.;
RT   "Identification of a recurrent mutation in GALNT3 demonstrates that
RT   hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are
RT   allelic disorders.";
RL   J. Mol. Med. 83:33-38(2005).
RN   [10]
RP   FUNCTION.
RX   PubMed=16638743; DOI=10.1074/jbc.m602469200;
RA   Kato K., Jeanneau C., Tarp M.A., Benet-Pages A., Lorenz-Depiereux B.,
RA   Bennett E.P., Mandel U., Strom T.M., Clausen H.;
RT   "Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis.
RT   Secretion of fibroblast growth factor 23 requires O-glycosylation.";
RL   J. Biol. Chem. 281:18370-18377(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide
CC       biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a
CC       serine or threonine residue on the protein receptor. Has activity
CC       toward HIV envelope glycoprotein gp120, EA2, Muc2 and Muc5. Probably
CC       glycosylates fibronectin in vivo. Glycosylates FGF23. Plays a central
CC       role in phosphate homeostasis. {ECO:0000269|PubMed:16638743,
CC       ECO:0000269|PubMed:9295285}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-seryl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = 3-O-
CC         [N-acetyl-alpha-D-galactosaminyl]-L-seryl-[protein] + H(+) + UDP;
CC         Xref=Rhea:RHEA:23956, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:12788,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:53604,
CC         ChEBI:CHEBI:58223, ChEBI:CHEBI:67138; EC=2.4.1.41;
CC         Evidence={ECO:0000269|PubMed:8663203};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-threonyl-[protein] + UDP-N-acetyl-alpha-D-galactosamine = 3-
CC         O-[N-acetyl-alpha-D-galactosaminyl]-L-threonyl-[protein] + H(+) +
CC         UDP; Xref=Rhea:RHEA:52424, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11689, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:58223,
CC         ChEBI:CHEBI:67138, ChEBI:CHEBI:87075; EC=2.4.1.41;
CC         Evidence={ECO:0000269|PubMed:8663203};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- PATHWAY: Protein modification; protein glycosylation.
CC   -!- INTERACTION:
CC       Q14435-2; Q92624: APPBP2; NbExp=3; IntAct=EBI-10232904, EBI-743771;
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus, Golgi stack membrane
CC       {ECO:0000269|PubMed:9394011}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:9394011}. Note=Resides preferentially in the trans
CC       and medial parts of the Golgi stack.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14435-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14435-2; Sequence=VSP_011202, VSP_011203;
CC   -!- TISSUE SPECIFICITY: Expressed in organs that contain secretory
CC       epithelial glands. Highly expressed in pancreas, skin, kidney and
CC       testis. Weakly expressed in prostate, ovary, intestine and colon. Also
CC       expressed in placenta and lung and fetal lung and fetal kidney.
CC       {ECO:0000269|PubMed:12708471, ECO:0000269|PubMed:8663203}.
CC   -!- DOMAIN: There are two conserved domains in the glycosyltransferase
CC       region: the N-terminal domain (domain A, also called GT1 motif), which
CC       is probably involved in manganese coordination and substrate binding
CC       and the C-terminal domain (domain B, also called Gal/GalNAc-T motif),
CC       which is probably involved in catalytic reaction and UDP-Gal binding.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The ricin B-type lectin domain binds to GalNAc and contributes
CC       to the glycopeptide specificity. {ECO:0000250}.
CC   -!- DISEASE: Tumoral calcinosis, hyperphosphatemic, familial, 1 (HFTC1)
CC       [MIM:211900]: A form of hyperphosphatemic tumoral calcinosis, a rare
CC       autosomal recessive metabolic disorder that manifests with
CC       hyperphosphatemia and massive calcium deposits in the skin and
CC       subcutaneous tissues. Some patients have recurrent, transient, painful
CC       swellings of the long bones associated with the radiographic findings
CC       of periosteal reaction and cortical hyperostosis and absence of skin
CC       involvement. {ECO:0000269|PubMed:15133511,
CC       ECO:0000269|PubMed:15599692}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Overexpressed in many differentiated carcinomas,
CC       suggesting that it may serve as a marker of tumor differentiation.
CC   -!- SIMILARITY: Belongs to the glycosyltransferase 2 family. GalNAc-T
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH56246.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Functional Glycomics Gateway - GTase;
CC       Note=Polypeptide N-acetylgalactosaminyltransferase 3;
CC       URL="http://www.functionalglycomics.org/glycomics/molecule/jsp/glycoEnzyme/viewGlycoEnzyme.jsp?gbpId=gt_hum_485";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X92689; CAA63371.1; -; mRNA.
DR   EMBL; AC009495; AAY14678.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11324.1; -; Genomic_DNA.
DR   EMBL; BC056246; AAH56246.1; ALT_INIT; mRNA.
DR   EMBL; BC113565; AAI13566.1; -; mRNA.
DR   EMBL; BC113567; AAI13568.1; -; mRNA.
DR   CCDS; CCDS2226.1; -. [Q14435-1]
DR   RefSeq; NP_004473.2; NM_004482.3. [Q14435-1]
DR   RefSeq; XP_005246506.1; XM_005246449.1. [Q14435-1]
DR   RefSeq; XP_011509231.1; XM_011510929.1. [Q14435-1]
DR   RefSeq; XP_016859259.1; XM_017003770.1. [Q14435-1]
DR   AlphaFoldDB; Q14435; -.
DR   SMR; Q14435; -.
DR   BioGRID; 108863; 25.
DR   IntAct; Q14435; 6.
DR   STRING; 9606.ENSP00000376465; -.
DR   BindingDB; Q14435; -.
DR   ChEMBL; CHEMBL4523291; -.
DR   CAZy; CBM13; Carbohydrate-Binding Module Family 13.
DR   CAZy; GT27; Glycosyltransferase Family 27.
DR   GlyConnect; 1620; 3 N-Linked glycans (1 site).
DR   GlyGen; Q14435; 3 sites, 3 N-linked glycans (1 site).
DR   iPTMnet; Q14435; -.
DR   PhosphoSitePlus; Q14435; -.
DR   BioMuta; GALNT3; -.
DR   DMDM; 209572629; -.
DR   EPD; Q14435; -.
DR   jPOST; Q14435; -.
DR   MassIVE; Q14435; -.
DR   MaxQB; Q14435; -.
DR   PaxDb; Q14435; -.
DR   PeptideAtlas; Q14435; -.
DR   PRIDE; Q14435; -.
DR   ProteomicsDB; 59988; -. [Q14435-1]
DR   ProteomicsDB; 59989; -. [Q14435-2]
DR   Antibodypedia; 2358; 171 antibodies from 24 providers.
DR   DNASU; 2591; -.
DR   Ensembl; ENST00000392701.8; ENSP00000376465.3; ENSG00000115339.14. [Q14435-1]
DR   GeneID; 2591; -.
DR   KEGG; hsa:2591; -.
DR   MANE-Select; ENST00000392701.8; ENSP00000376465.3; NM_004482.4; NP_004473.2.
DR   UCSC; uc010fph.2; human. [Q14435-1]
DR   CTD; 2591; -.
DR   DisGeNET; 2591; -.
DR   GeneCards; GALNT3; -.
DR   GeneReviews; GALNT3; -.
DR   HGNC; HGNC:4125; GALNT3.
DR   HPA; ENSG00000115339; Tissue enhanced (stomach).
DR   MalaCards; GALNT3; -.
DR   MIM; 211900; phenotype.
DR   MIM; 601756; gene.
DR   neXtProt; NX_Q14435; -.
DR   OpenTargets; ENSG00000115339; -.
DR   Orphanet; 306661; Familial hyperphosphatemic tumoral calcinosis/Hyperphosphatemic hyperostosis syndrome.
DR   PharmGKB; PA28538; -.
DR   VEuPathDB; HostDB:ENSG00000115339; -.
DR   eggNOG; KOG3736; Eukaryota.
DR   GeneTree; ENSGT00940000156609; -.
DR   InParanoid; Q14435; -.
DR   OMA; NGEHPNL; -.
DR   OrthoDB; 606683at2759; -.
DR   PhylomeDB; Q14435; -.
DR   TreeFam; TF313267; -.
DR   BRENDA; 2.4.1.41; 2681.
DR   PathwayCommons; Q14435; -.
DR   Reactome; R-HSA-190372; FGFR3c ligand binding and activation.
DR   Reactome; R-HSA-5083625; Defective GALNT3 causes HFTC.
DR   Reactome; R-HSA-913709; O-linked glycosylation of mucins.
DR   SignaLink; Q14435; -.
DR   UniPathway; UPA00378; -.
DR   BioGRID-ORCS; 2591; 11 hits in 1067 CRISPR screens.
DR   ChiTaRS; GALNT3; human.
DR   GeneWiki; GALNT3; -.
DR   GenomeRNAi; 2591; -.
DR   Pharos; Q14435; Tbio.
DR   PRO; PR:Q14435; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q14435; protein.
DR   Bgee; ENSG00000115339; Expressed in mucosa of sigmoid colon and 147 other tissues.
DR   ExpressionAtlas; Q14435; baseline and differential.
DR   Genevisible; Q14435; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0032580; C:Golgi cisterna membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0030145; F:manganese ion binding; IDA:BHF-UCL.
DR   GO; GO:0004653; F:polypeptide N-acetylgalactosaminyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0005975; P:carbohydrate metabolic process; NAS:ProtInc.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0016266; P:O-glycan processing; TAS:Reactome.
DR   GO; GO:0006493; P:protein O-linked glycosylation; IMP:GO_Central.
DR   GO; GO:0018242; P:protein O-linked glycosylation via serine; IDA:BHF-UCL.
DR   GO; GO:0018243; P:protein O-linked glycosylation via threonine; IDA:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   CDD; cd02510; pp-GalNAc-T; 1.
DR   CDD; cd00161; RICIN; 1.
DR   Gene3D; 3.90.550.10; -; 1.
DR   InterPro; IPR045885; GalNAc-T.
DR   InterPro; IPR001173; Glyco_trans_2-like.
DR   InterPro; IPR029044; Nucleotide-diphossugar_trans.
DR   InterPro; IPR035992; Ricin_B-like_lectins.
DR   InterPro; IPR000772; Ricin_B_lectin.
DR   Pfam; PF00535; Glycos_transf_2; 1.
DR   Pfam; PF00652; Ricin_B_lectin; 1.
DR   SMART; SM00458; RICIN; 1.
DR   SUPFAM; SSF50370; SSF50370; 1.
DR   SUPFAM; SSF53448; SSF53448; 1.
DR   PROSITE; PS50231; RICIN_B_LECTIN; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Disease variant; Disulfide bond; Glycoprotein;
KW   Glycosyltransferase; Golgi apparatus; Lectin; Manganese; Membrane;
KW   Metal-binding; Reference proteome; Signal-anchor; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..633
FT                   /note="Polypeptide N-acetylgalactosaminyltransferase 3"
FT                   /id="PRO_0000059106"
FT   TOPO_DOM        1..19
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        20..37
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        38..633
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          504..630
FT                   /note="Ricin B-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   REGION          184..293
FT                   /note="Catalytic subdomain A"
FT   REGION          356..418
FT                   /note="Catalytic subdomain B"
FT   BINDING         225
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         254
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         277
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250"
FT   BINDING         279
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250"
FT   BINDING         387
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         415
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250"
FT   BINDING         418
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        132
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        297
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        484
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        173..410
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DISULFID        401..482
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DISULFID        517..535
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DISULFID        561..574
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   DISULFID        605..618
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00174"
FT   VAR_SEQ         173..192
FT                   /note="CIEQKFKRCPPLPTTSVIIV -> YVEEYLLFILYHQALQGREG (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011202"
FT   VAR_SEQ         193..633
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_011203"
FT   VARIANT         162..633
FT                   /note="Missing (in HFTC1)"
FT                   /evidence="ECO:0000269|PubMed:15133511"
FT                   /id="VAR_080832"
FT   CONFLICT        481
FT                   /note="Q -> R (in Ref. 1; CAA63371)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   633 AA;  72610 MW;  3019B2DCCC19A584 CRC64;
     MAHLKRLVKL HIKRHYHKKF WKLGAVIFFF IIVLVLMQRE VSVQYSKEES RMERNMKNKN
     KMLDLMLEAV NNIKDAMPKM QIGAPVRQNI DAGERPCLQG YYTAAELKPV LDRPPQDSNA
     PGASGKAFKT TNLSVEEQKE KERGEAKHCF NAFASDRISL HRDLGPDTRP PECIEQKFKR
     CPPLPTTSVI IVFHNEAWST LLRTVHSVLY SSPAILLKEI ILVDDASVDE YLHDKLDEYV
     KQFSIVKIVR QRERKGLITA RLLGATVATA ETLTFLDAHC ECFYGWLEPL LARIAENYTA
     VVSPDIASID LNTFEFNKPS PYGSNHNRGN FDWSLSFGWE SLPDHEKQRR KDETYPIKTP
     TFAGGLFSIS KEYFEYIGSY DEEMEIWGGE NIEMSFRVWQ CGGQLEIMPC SVVGHVFRSK
     SPHSFPKGTQ VIARNQVRLA EVWMDEYKEI FYRRNTDAAK IVKQKAFGDL SKRFEIKHRL
     QCKNFTWYLN NIYPEVYVPD LNPVISGYIK SVGQPLCLDV GENNQGGKPL IMYTCHGLGG
     NQYFEYSAQH EIRHNIQKEL CLHAAQGLVQ LKACTYKGHK TVVTGEQIWE IQKDQLLYNP
     FLKMCLSANG EHPSLVSCNP SDPLQKWILS QND
//
